公开(公告)号：US20200172525A1

公开(公告)日：2020-06-04

申请号：US16787471

申请日：2020-02-11

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Didier SCHERRER ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D215/38 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12 ,  C07D217/02 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/42 ,  C07D215/46

摘要： The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

公开(公告)号：US20210300871A1

公开(公告)日：2021-09-30

申请号：US17259483

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D213/38 ,  C07D401/12 ,  C07D241/12 ,  C07D213/75 ,  C07D239/42 ,  C07C233/65 ,  C07D213/81 ,  A61P31/12

摘要： A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

公开(公告)号：US20180339981A1

公开(公告)日：2018-11-29

申请号：US16050551

申请日：2018-07-31

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Didier SCHERRER ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D215/46 ,  C07D215/42 ,  C07D213/74 ,  A61K31/4985 ,  A61K31/4709 ,  C07D403/12 ,  C07D401/12 ,  C07D241/44 ,  C07D215/38 ,  C07D217/02

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20170226095A1

公开(公告)日：2017-08-10

申请号：US15486836

申请日：2017-04-13

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D217/02 ,  C07D401/12 ,  C07D403/12 ,  C07D215/38 ,  C07D241/44

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20220356175A1

公开(公告)日：2022-11-10

申请号：US17259370

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D413/12 ,  C07D239/16 ,  C07D405/12 ,  C07D239/22 ,  C07D403/12 ,  C07D401/12

摘要： A compound of formula (Ic) wherein X2 represents a —CO—NRk— group, wherein Rk represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH2)s—O—, a —CO— group, a —SO2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO2— or a —SO2—NH— group; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a a group, a group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.

公开(公告)号：US20220127253A1

公开(公告)日：2022-04-28

申请号：US17327079

申请日：2021-05-21

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D215/38 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12 ,  C07D217/02 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/42 ,  C07D215/46

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20210309611A1

公开(公告)日：2021-10-07

申请号：US17259364

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

摘要： A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(═O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

公开(公告)号：US20210122732A1

公开(公告)日：2021-04-29

申请号：US17259451

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D205/04 ,  C07F7/18 ,  C07C237/40 ,  C07C255/50 ,  C07D213/81 ,  C07D213/74 ,  C07C311/16

摘要： A compound of formula (Ie): wherein Y1 represents an aryl group, X2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH3)NH— group, a —C(OH)(CH2OH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO2— group, or a —SO2—NH— group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a —CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(ORf)(OR′f) group, wherein Rf and R′f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a —Si(CH3)3 group, a —NHCOO—(C1-C4)alkyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

公开(公告)号：US20240308964A1

公开(公告)日：2024-09-19

申请号：US18660578

申请日：2024-05-10

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

CPC分类号： C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

摘要： A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification




wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(═O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

公开(公告)号：US20240343716A1

公开(公告)日：2024-10-17

申请号：US18435619

申请日：2024-02-07

申请人： ABIVAX ,  CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:




where:



R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group;
R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and
R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.